Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.85, moving -3.27% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.33%. On ...
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...
This is this week’s ForbesWomen newsletter, which every Thursday brings news about the world’s top female entrepreneurs, leaders and investors straight to your inbox. Click here to get on the ...
Get started with Java streams, including how to create streams from Java collections, the mechanics of a stream pipeline, examples of functional programming with Java streams, and more. You can think ...
After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Recursion Pharmaceuticals, Inc. is one of them. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a ...
The $12.5 million equity milestone payment is payable by Recursion pursuant to the previously announced agreement under which Rallybio sold its interest in the REV102 program to Recursion for up to ...
In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results